Today’s issue of WorkCompRecap features Enlyte’s release of the second portion of its 2021 Mitchell Pharmacy Solutions Drug Trends Series Report, which examines the trends within combined in-network and out-of-network channels to address the total view of prescription activity.
Key findings included that both out-of-network prescription utilization and cost decreased slightly from 2020 (down 1.2 & 1.4 points respectively); generic utilization remained relatively flat, while generic efficiency increased 0.1 points from 2020, to 98.3%; and 7 of the top 10 therapeutic classes by cost were also in the top 10 for utilization. Other key highlights included that 7 of the top 10 therapeutic classes saw decreased utilization and cost per claim in 2021, with the opioid and antiulcer classes falling by more than 10% on both metrics.